Search
Showing results for "lung disease preterm"
MEDIA ENQUIRIES Media Contacts About the Wal-yan Respiratory Research Centre Please direct general enquiries to our reception on (08) 6319 1000.
Determine whether inhaled albuterol sulfate (salbutamol sulfate) premedication decreases the risk of perioperative respiratory adverse events
The Western Australian Epithelial Research Program (WAERP) biobank is undertaking a number of research projects intended to improve the understanding and preclinical assessment of therapeutics for respiratory conditions.
These findings indicate that early CF lung disease is characterized by an increased mucus burden and inflammatory markers without infection or structural lung disease
One way the Wal-yan Respiratory Research Centre provides the opportunity for consumers and community members to contribute to our research is through participation in one of our eight community reference groups.
Co-Head, Foundations of Lung Disease
Despite our current treatment, many cystic fibrosis (CF) patients still show progressive bronchiectasis and small airways disease.
Our findings suggest that prenatal exposure to inflammation may alter the risk of sepsis in preterm infants partly by modulation of monocyte responses to pathogens
André Schultz MBChB, PhD, FRACP Head, BREATH Team Head, BREATH Team Prof André Schultz is the Head, BREATH Team at The Kids Research Institute
Bronchopulmonary dysplasia (BPD) remains the most common complication of preterm birth with lifelong consequences. Multiple BPD definitions are currently used in daily practice. Uniformity in defining BPD is important for clinical care, research and benchmarking. The aim of this Delphi procedure is to determine what clinicians and researchers consider the key features for defining BPD.